A 28-year-old man with newly diagnosed pulmonary tuberculosis is started on standard first-line antitubercular therapy. Two weeks into treatment, he develops severe hepatotoxicity with jaundice, dark urine, and abdominal pain. Liver function tests show: AST 480 U/L, ALT 520 U/L, ALP 95 U/L, total bilirubin 4.2 mg/dL, albumin 3.8 g/dL. All four first-line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) are suspected. Which drug should be reintroduced FIRST after recovery, and what is the rationale?

Explanation

## Drug-Induced Hepatotoxicity in Antitubercular Therapy ### Hepatotoxic Potential of First-Line Drugs | Drug | Hepatotoxicity Risk | Mechanism | Frequency | |------|-------------------|-----------|----------| | **Pyrazinamide** | **Highest** | Converted to uric acid; direct hepatocyte injury | 1–5% | | **Rifampicin** | High | Enzyme inducer; metabolite-mediated injury | 0.5–3% | | **Isoniazid** | Moderate | Acetylation-dependent metabolite; idiosyncratic | 0.5–2% | | **Ethambutol** | **Lowest** | Minimal hepatic metabolism | <0.5% | **High-Yield:** Ethambutol is the safest drug to reintroduce first because it has the lowest hepatotoxic potential and does not compromise TB treatment efficacy when used as monotherapy during the reintroduction phase. ### Approach to Drug-Induced Hepatotoxicity in TB ```mermaid flowchart TD A["Hepatotoxicity suspected<br/>(AST/ALT >5× ULN or<br/>bilirubin >3 mg/dL)"]:::outcome --> B["Stop all four drugs<br/>immediately"]:::urgent B --> C{"Liver function<br/>recovery?"}:::decision C -->|"Yes, after 1-2 weeks"| D["Reintroduce in order of<br/>hepatotoxic risk<br/>Ethambutol → Isoniazid →<br/>Rifampicin → Pyrazinamide"]:::action D --> E["Monitor LFTs after<br/>each drug addition<br/>3-5 day intervals"]:::action C -->|"No improvement"| F["Investigate alternative<br/>causes; consider<br/>second-line agents"]:::action E --> G{"Hepatotoxicity<br/>recurs?"}:::decision G -->|"Yes"| H["Omit offending drug;<br/>continue others"]:::action G -->|"No"| I["Continue standard<br/>regimen"]:::outcome ``` ### Rationale for Ethambutol First 1. **Lowest hepatotoxicity:** Ethambutol undergoes minimal hepatic metabolism and has the safest profile. 2. **Maintains TB efficacy:** Although ethambutol is bacteriostatic (not bactericidal), it prevents the emergence of resistance and is essential in the intensive phase. 3. **Allows safe monitoring:** Starting with the safest drug allows clinicians to assess individual drug tolerance before reintroducing more hepatotoxic agents. 4. **Standard protocol:** WHO and Indian TB guidelines recommend reintroduction in order of increasing hepatotoxic risk. ### Reintroduction Protocol **Clinical Pearl:** Reintroduce one drug every 3–5 days, monitoring liver function tests after each addition. If hepatotoxicity recurs with a specific drug, that drug is omitted and the regimen is adjusted accordingly. **Sequence of reintroduction:** 1. **Ethambutol** (safest) 2. **Isoniazid** (moderate risk) 3. **Rifampicin** (high risk) 4. **Pyrazinamide** (highest risk; may be permanently omitted if hepatotoxicity recurs) ### Management if Hepatotoxicity Recurs If hepatotoxicity recurs upon reintroduction: - **Omit the offending drug** and continue with the others - If pyrazinamide is the culprit: extend intensive phase to 3 months (without pyrazinamide) and continue standard continuation phase - If rifampicin is the culprit: use second-line drugs (fluoroquinolones, ethionamide, linezolid) - If isoniazid is the culprit: use second-line agents; isoniazid is irreplaceable in standard regimens **Mnemonic for hepatotoxicity risk — PRIYE (highest to lowest):** - **P** (Pyrazinamide): Highest - **R** (Rifampicin): High - **I** (Isoniazid): Moderate - **Y** (Y... none) - **E** (Ethambutol): Lowest [cite:KD Tripathi 8e Ch 47; Park 26e Ch 6] ## Why the Correct Answer is Correct Ethambutol has the lowest hepatotoxic potential among first-line antitubercular drugs and undergoes minimal hepatic metabolism. It is the safest drug to reintroduce first, allowing safe monitoring before reintroducing more hepatotoxic agents. This approach maintains TB treatment efficacy while minimizing the risk of recurrent hepatotoxicity.